GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Capex-to-Operating-Income

Vivos (RDGL) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Vivos Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Vivos's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-0.86 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Vivos Capex-to-Operating-Income Historical Data

The historical data trend for Vivos's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Capex-to-Operating-Income Chart

Vivos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivos Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivos's Capex-to-Operating-Income

For the Medical Devices subindustry, Vivos's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Vivos's Capex-to-Operating-Income falls into.


;
;

Vivos Capex-to-Operating-Income Calculation

Vivos's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -2.604
=N/A

Vivos's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.864
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos  (OTCPK:RDGL) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Vivos Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Vivos's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Business Description

Traded in Other Exchanges
N/A
Address
1030 N Center Parkway, Kennewick, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336